EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary

Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; F Marchesi; Riccardo Capocaccia

doi:10.1016/j.ejca.2008.11.018

Keywords

CancerMedicineOncologyInternal medicine

Affiliated Institutions

Related Publications

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura , Isamu Okamoto , Tatsuhiko Kashii +13 more

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients ...

2008 British Journal of Cancer 203 citations

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

Keunchil Park , Kōichi Goto

In the majority of these reports, objective response rates of > 25% and disease control rates of > 60% have been described. Treatment with gefitinib resulted in a median time to...

2006 Current Medical Research and Opinion 92 citations

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations

Lecia V. Sequist , Renato Martins , David R. Spigel +16 more

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR ...

2008 Journal of Clinical Oncology 829 citations

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Akira Inoue , Takuji Suzuki , Tatsuro Fukuhara +6 more

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) h...

2006 Journal of Clinical Oncology 503 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch , Marileila Varella‐Garcia , Paul A. Bunn +16 more

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cance...

2006 Journal of Clinical Oncology 702 citations

Publication Info

Year: 2009
Type: article
Volume: 45
Issue: 6
Pages: 931-991
Citations: 1011
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1011

OpenAlex

Cite This

APA Style

                            
                                
                                    Milena Sant, 
                                
                                    Claudia Allemani, 
                                
                                    Mariano Santaquilani
                                
                                et al.
                            
                            (2009). 
                            EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. 
                            European Journal of Cancer
                            , 45
                            (6)
                            , 931-991.
                            https://doi.org/10.1016/j.ejca.2008.11.018
                        

Identifiers

DOI: 10.1016/j.ejca.2008.11.018